SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target

Shi, John; Bodo, Juraj; Zhao, Xiaoxian; Durkin, Lisa; Goyal, Tanu; Meyerson, Howard; Hsi, Eric D.

doi:10.1111/bjh.15393

Cited by 11 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients who are chemorefractory in whom autologous SCT is not feasible, there is a single case report of an allogeneic SCT with cord blood transplantation achieving durable remission [16]. Recent data show SLAMF2 (CD319/CS1), targetable by elotuzumab, is expressed in PBL and has been proposed as a potential therapeutic target [17].…”

Section: Discussionmentioning

confidence: 99%

A Rare Presentation of HIV-Negative Plasmablastic Lymphoma: A Diagnostic Dilemma

Kessler

Marcellino

Niglio

et al. 2019

Case Reports in Hematology

View full text Add to dashboard Cite

Plasmablastic lymphoma (PBL) and plasmablastic plasma cell myeloma (PCM) have many overlapping characteristics. Clinical correlation can help make the distinction between the two entities. Human immunodeficiency virus- (HIV-) negative PBL is a rare disease, making the diagnosis more challenging. While there is no standard of care for PBL, current recommendations include dose-adjusted EPOCH (etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone), with or without bortezomib. We report an aggressive case of HIV-negative plasmablastic lymphoma and discuss the challenge in establishing a diagnosis. We review the literature regarding this disease and current recommendations for treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

A Rare Presentation of HIV-Negative Plasmablastic Lymphoma: A Diagnostic Dilemma

Kessler

Marcellino

Niglio

et al. 2019

Case Reports in Hematology

View full text Add to dashboard Cite

show abstract

“…Elotuzumab, a therapeutic anti-SLAMF7/CD319 antibody, induced dose-dependent ADCC activity toward BC2 target cells, using PBMCs as effector cells. Elotuzumab also enhanced granzyme B release from PBMC effector cells against BC2 cells [64]. Panaampon et al (2022) analyzed the expression of SLAMF7/CD319 by flow cytometry in a panel of primary effusion lymphoma cell lines (BCBL-1, BC-1, BC-2, BC-3, RM-P1, GTO, and TY-1), multiple myeloma cell lines (KMM-1, KMS-12-PE, RPMI-8226, U266, MM1.S, MM1.R, KMS-11, NCI-H929, JJN-3, and IM-9) and a mantle cell lymphoma (MCL) cell line (Z138) [65].…”

Section: Slamf7/cd319 (Cs1 Cracc 19a24)mentioning

confidence: 98%

“…The expression of SLAMF7/CD319 was also reported in plasmablastic lymphoma (PBL) [64]. Shi et al (2018) used immunohistochemistry to analyze 20 PBL cases, including 11 PBL not otherwise specified (PBL NOS), 5 HIV+ PBL, 2 ALK+ large B cell lymphomas (LBCL), 1 primary effusion lymphoma, and 1 PBL with angioimmunoblastic T cell lymphoma (AITL).…”

Section: Slamf7/cd319 (Cs1 Cracc 19a24)mentioning

confidence: 99%

SLAM Family Receptors in B Cell Chronic Lymphoproliferative Disorders

Kľoc,

Kurhajec,

Huniadi

et al. 2024

IJMS

View full text Add to dashboard Cite

The signaling lymphocytic activation molecule (SLAM) receptor family (SLAMF) consists of nine glycoproteins that belong to the CD2 superfamily of immunoglobulin (Ig) domain-containing molecules. SLAMF receptors modulate the differentiation and activation of a wide range of immune cells. Individual SLAMF receptors are expressed on the surface of hematopoietic stem cells, hematopoietic progenitor cells, B cells, T cells, NK cells, NKT cells, monocytes, macrophages, dendritic cells, neutrophils, and platelets. The expression of SLAMF receptors was studied during normal B cell maturation. Several SLAMF receptors were also detected in cancer cell lines of B-lymphoid origin and in pathological B cells from patients with B cell chronic lymphoproliferative disorders (B-CLPD), the most frequent hematological malignancies in adults. This review summarizes current knowledge on the expression of SLAMF receptors and their adaptor proteins SAP and EAT-2 in B-CLPD. Several SLAMF receptors could be regarded as potential diagnostic and differential diagnostic markers, prognostic factors, and targets for the development of novel drugs for patients with B-CLPD.

show abstract

“…Shi et al. ( 72 ) found that SLAMF7(CD319/CS1) was detected in PBL, suggesting that it may serve as a potential diagnostic marker and therapeutic target for PBL. MYC rearrangement was observed in around half of the patients and this abnormality could inhibit transcription factor BLIMP-1 and thus promote tumor cell proliferation ( 73 ).…”

Section: Treatmentmentioning

confidence: 99%

Plasmablastic lymphoma: current knowledge and future directions

Li,

Peng,

Zhou

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Plasmablastic lymphoma (PBL) is an aggressive non-Hodgkin lymphoma associated with HIV infection and immunodeficiency. However, PBL can also be seen immunocompetent individuals in recent studies. PBL was characterized by distinct clinical and pathological features, such as plasmablastic morphology and universal expression of plasma cell markers. The clinicopathologic features were different between HIV-negative and HIV-positive patients. Gene expression analysis identified the unique molecular feature in PBL, including frequent c-MYC rearrangement and downregulation of BCR signaling pathway. Despite the recent advances in the treatment of PBL, the prognosis of PBL patients remains dismal. The objectives of this review are to summarize the current knowledge on the epidemiology, molecular profiles, clinical and pathological features, differential diagnosis, treatment strategies, prognostic factors, and potential novel therapeutic approaches in PBL patients.

show abstract

SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target

Cited by 11 publications

References 10 publications

A Rare Presentation of HIV-Negative Plasmablastic Lymphoma: A Diagnostic Dilemma

A Rare Presentation of HIV-Negative Plasmablastic Lymphoma: A Diagnostic Dilemma

SLAM Family Receptors in B Cell Chronic Lymphoproliferative Disorders

Plasmablastic lymphoma: current knowledge and future directions

Contact Info

Product

Resources

About